NCT07691177已完成1 期
An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Oral Bioequivalence Study of Imeglimin HCl 500 mg Film Coated Tablets and Twymeeg Tablets 500 mg in Healthy, Adult, Human Participants Under Fasting Condition.
Humanis Saglık Anonim Sirketi1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2026年2月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Peak Plasma Concentration (Cmax)
研究概览
简要总结
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, Two way crossover, Oral Bioequivalence Study of Imeglimin HCl 500 mg Film Coated Tablets of Humanis Sağlık A.Ş., Ç.O.S.B. Karaağaç Mahallesi Fatih Bulvarı No:32 Kapaklı/TEKİRDAĞ and Twymeeg Tablets 500 mg of Sumitomo Pharma Co., Ltd. 2-6-8, Dosho-machi, Chuo-Ward, Osaka City, in Healthy, Adult, Human Participants Under Fasting Condition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants aged between 18 to 45 years (both inclusive).
- •Participants' weight within normal range according to normal values for Body Mass Index (between 18.5 to 30.0 kg/m2) (both inclusive) with minimum of 45 kg weight.
- •Participants with normal health as determined by personal medical history, clinical examination and laboratory examinations within Predefined site Normal range [Annexure III].
- •Participants having clinically acceptable 12-lead electrocardiogram (ECG).
- •Participants having clinically acceptable chest X-Ray (PA view), if taken.
- •Participants having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine and morphine).
- •Participants having negative urine alcohol test / breath alcohol test.
- •Non-smoker.
- •Participants willing to adhere to the protocol requirements and to provide written informed consent.
- •For male Participants:
- •1-Participants willing to follow approved birth control methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Participants willing to refrain from donating sperm during the study period
- •For Female Participants:
- •Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral tubal ligation or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam
- •Postmenopausal for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above
- •Participants having negative urine pregnancy test at screening and negative serum ƒÒ-hCG pregnancy test on admission day of period 01 (only for female Participants).
排除标准
- •Hypersensitivity to Imeglimin or related class of drugs or any of its excipients or heparin.
- •History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
- •Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period
- •Presence of alcoholism or drug abuse.
- •History or presence of asthma, urticaria or other significant allergic reactions.
- •History or presence of significant gastric and/or duodenal ulceration.
- •History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
- •History or presence of cancer or basal or squamous cell carcinoma.
- •Difficulty with donating blood.
- •Difficulty in swallowing solids dosage form like tablets or capsules.
- •Use of any prescribed medication or OTC medication including vaccines, vitamins and herbal remedies during last 30 days prior to admission in period
- •Major illness within past 3 months.
- •Participant who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.
- •Consumption of xanthine-containing products, tobacco containing products or alcohol or any alcohol containing products within 48.00 hours prior to admission in period
- •Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period
- •Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
- •History or presence of significant easy bruising or bleeding.
- •History or presence of significant recent trauma.
- •Participants who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
- •Female Participants who are currently breast feeding.
结局指标
主要结局
Peak Plasma Concentration (Cmax)
时间窗: 72.00 hours
Acceptance range for bioequivalence was 80.00%-125.00% for 90% confidence intervals for the geometric least square mean ratio for Cmax.
Area Under the Curve from time zero to time of last measurable concentration (AUC0-t)
时间窗: 72.00 hour
Acceptance range for bioequivalence was 80.00%-125.00% for 90% confidence intervals for the geometric least square mean ratio for AUC0-t.
次要结局
- Area Under the Curve from time zero to time infinite (AUC0-∞)(72.00 hour)
- Time to reach peak plasma concentration (Tmax)(72.00 hours)
- Plasma Elimination Half-Life (t1/2)(72.00 hours)
- Kel(72.00 hours)
- AUC0-t/ AUC0-∞(72 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets in Healthy, Adult, Human Subjects Under Fed Condition.Type 2 DiabetesNCT07266779Humanis Saglık Anonim Sirketi36
已完成
1 期
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mgNCT07266766Humanis Saglık Anonim Sirketi40
尚未招募
不适用
An Open Label Single Dose Two Treatment Two Period Two Way Crossover Oral Bioequivalence Study Comparing Valsartan/Hydrochlorothiazide Tablets USP 320 mg/25 mg In Healthy Adult Human Subjects Under Fasting ConditionsCTRI/2025/01/079266Incepta Pharmaceuticals Ltd16
尚未招募
不适用
A bioequivalence study of Prazosin Hydrochloride tablets 5 mg in healthy human adult subjects under fasting conditionsCTRI/2025/04/083888Pfizer Limited,28
已完成
不适用
An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Single Period Parallel Truncated Oral Bioequivalence Design In Adult Patient With Mild And Moderate Iron Deficiency Anemia Under Fed Conditions study comparing Iron III Hydroxide Polymaltose 100 mg TabletCTRI/2025/01/079590Assist Pro36